

Oxervate

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Pa	tient's Name:	Date:	
Patient's Name:		Patient's Date of Birth:	
Ph	ysician's Name:		
Sp	ysician's Name:ecialty:	NPI#:	 -
Pn	iysician Office Telephone:	Pnysician Office Fax:	
Re	equest Initiated For:	_	
1.	What is the diagnosis? ☐ Neurotrophic keratitis ☐ Other		
2.	What is the ICD-10 code?		
3.	What is the severity of the neurotrophic keratit	tis? 🗆 Stage 1 🗀 Stage 2 🗀 Stage 3 🖵 C	Other
4.	Did the patient experience persistent epithelial defects (PED) or corneal ulceration of at least 2 weeks duration refractory to one or more conventional non-surgical treatments (e.g., preservative free artificial tears)? Yes □ No		
5.	Does the patient have evidence of decreased coaesthesiometer) within the area of the PED or corneal quadrant? \square Yes \square No		
6.	Has the patient received a previous course of C ☐ Yes ☐ No If No, no further questions	Oxervate in the affected eye?	
7.	Is the patient currently receiving treatment in t	the affected eye? 🗖 Yes 📮 No	
8.	How many weeks of Oxervate therapy has the	patient received for the affected eye?	weeks
	uttest that this information is accurate and t formation is available for review if requeste		
·	• • •	ea by CVS Caremark or the benefit plan :	sponsor.
X_ Dr	rescriber or Authorized Signature	Date (mm/dd/	

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization. Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Oxervate SGM - 6/2020.